Reports world wide Meningococcal Vaccines Disease | Page 2

PRODUCT PROFILE ( LATE STAGE ): MEN QUAD TT PRODUCT PROFILE ( LATE STAGE ): MENABCW-135Y
LIST OF FIGURES Figure 1 : Meningococcal vaccines market value across the US and five major EU markets , by country , 2016 – 25 Figure 2 : Total sales of meningococcal vaccines in the US , by risk group , 2016 – 25 Figure 3 : Total sales of MenB vaccines across the US and five major EU markets , by country , 2016 – Figure 4 : Total sales of meningococcal vaccines across the US and five major EU markets , by class , 2016 – 25 Figure 5 : Patient-based forecasting methodology for meningococcal vaccines Figure 6 : Price sources and calculations in the EU , by country Figure 7 : Total sales of meningococcal vaccines in the US , by risk group , 2016 – 25 Figure 8 : Total sales of meningococcal vaccines in the US , by class , 2016 – 25 Figure 9 : Meningococcal vaccination coverage in the US , by risk group , 2016 – 25 Figure 10 : Total sales of meningococcal vaccines in France , by class , 2016 – 25 Figure 11 : Meningococcal vaccination coverage in France , by risk group , 2016 – 25 Figure 12 : Total sales of meningococcal vaccines in Germany , by class , 2016 – 25 Figure 13 : Meningococcal vaccination coverage in Germany , by risk group , 2016 – 25 Figure 14 : Total sales of meningococcal vaccines in Italy , by class , 2016 – 25 Figure 15 : Meningococcal vaccination coverage in Italy , by risk group , 2016 – 25 Figure 16 : Total sales of meningococcal vaccines in Spain , by class , 2016 – 25 Figure 17 : Meningococcal vaccination coverage in Spain , by risk group , 2016 – 25 Figure 18 : Total sales of meningococcal vaccines in the UK , by class , 2016 – 25 Figure 19 : Meningococcal vaccination coverage in the UK , by risk group , 2016 – 25 Figure 20 : Bexsero for meningococcal disease – SWOT analysis Figure 21 : Menactra for meningococcal disease – SWOT analysis Figure 22 : Menveo for meningococcal disease – SWOT analysis Figure 23 : Nimenrix for meningococcal disease – SWOT analysis Figure 24 : Trumenba for meningococcal disease – SWOT analysis Figure 25 : Men Quad TT for meningococcal vaccination – SWOT analysis Figure 26 : MenABCW-135Y for meningococcal vaccination – SWOT analysis
LIST OF TABLES Table 1 : Meningococcal vaccines market value across the US and five major EU markets , by country ($ m ), 2016 – 25 Table 2 : Total sales of meningococcal vaccines in the US , by risk group ($ m ), 2016 – 25 Table 3 : Total sales of MenB vaccines across the US and five major EU markets , by country ($ m ), 2016 – 25 Table 4 : Total sales of meningococcal vaccines across the US and five major EU markets , by class ($ m ), 2016 – 25 Table 5 : Recommendations for meningococcal vaccination by national authorities , 2017 Table 6 : Total sales of meningococcal vaccines in the US , by risk group ($ m ), 2016 – 25 Table 7 : Total sales of meningococcal vaccines in the US , by class ($ m ), 2016 – 25 Table 8 : US meningococcal vaccines market forecast , 2016 – 25 Table 9 : US meningococcal vaccination coverage rates in recommended risk groups , 2016 – 25 Table 10 : Total sales of meningococcal vaccines in France , by class ($ m ), 2016 – 25 Table 11 : France meningococcal vaccines market forecast , 2016 – 25 Table 12 : France meningococcal vaccination coverage rates in recommended risk groups , 2016 – 25 Table 13 : Total sales of meningococcal vaccines in Germany , by class ($ m ), 2016 – 25 Table 14 : Germany meningococcal vaccines market forecast , 2016 – 25 Table 15 : Germany meningococcal vaccination coverage rates in recommended risk groups , 2016 – 25 Table 16 : Total sales of meningococcal vaccines in Italy , by class ($ m ), 2016 – 25 Table 17 : Italy meningococcal vaccines market forecast , 2016 – 25 Table 18 : Italy meningococcal vaccination coverage rates in recommended risk groups , 2016 – 25 Table 19 : Total sales of meningococcal vaccines in Spain , by class ($ m ), 2016 – 25 Table 20 : Spain meningococcal vaccines market forecast , 2016 – 25 Table 21 : Spain meningococcal vaccination coverage rates in recommended risk groups , 2016 – 25